

Nicholas J Ashton

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5436535/publications.pdf>

Version: 2024-02-01

163
papers

8,171
citations

46984

47
h-index

62565

80
g-index

176
all docs

176
docs citations

176
times ranked

6341
citing authors

#	ARTICLE	IF	CITATIONS
1	Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma A β ₄₂ /A β ₄₀ and p τ . Alzheimer's and Dementia, 2022, 18, 283-293.	0.4	72
2	Apolipoprotein B is a novel marker for early tau pathology in Alzheimer's disease. Alzheimer's and Dementia, 2022, 18, 875-887.	0.4	22
3	Diagnostic and prognostic plasma biomarkers for preclinical Alzheimer's disease. Alzheimer's and Dementia, 2022, 18, 1141-1154.	0.4	89
4	The extent of neuroradiological findings in COVID-19 shows correlation with blood biomarkers, Glasgow coma scale score and days in intensive care. Journal of Neuroradiology, 2022, 49, 421-427.	0.6	13
5	Association of Plasma p-tau181 and p-tau231 Concentrations With Cognitive Decline in Patients With Probable Dementia With Lewy Bodies. JAMA Neurology, 2022, 79, 32.	4.5	38
6	Validation of the LUMIPULSE automated immunoassay for the measurement of core AD biomarkers in cerebrospinal fluid. Clinical Chemistry and Laboratory Medicine, 2022, 60, 207-219.	1.4	44
7	Gfap and tau protein as predictors of neurological outcome after out-of-hospital cardiac arrest: A post hoc analysis of the COMACARE trial. Resuscitation, 2022, 170, 141-149.	1.3	13
8	Plasma p τ ₁₈₁ shows stronger network association to Alzheimer's disease dementia than neurofilament light and total tau. Alzheimer's and Dementia, 2022, 18, 1523-1536.	0.4	18
9	N-terminal and mid-region tau fragments as fluid biomarkers in neurological diseases. Brain, 2022, 145, 2834-2848.	3.7	20
10	Plasma p τ ₂₃₁ , p τ ₁₈₁ , τ -PET Biomarkers, and Cognitive Change in Older Adults. Annals of Neurology, 2022, 91, 548-560.	2.8	42
11	Is amyloid involved in acute neuroinflammation? A CSF analysis in encephalitis. Alzheimer's and Dementia, 2022, , .	0.4	3
12	Amyloid processing in τ -associated neurological syndromes. Journal of Neurochemistry, 2022, 161, 146-157.	2.1	35
13	Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer's disease. EBioMedicine, 2022, 76, 103836.	2.7	65
14	The accuracy and robustness of plasma biomarker models for amyloid PET positivity. Alzheimer's Research and Therapy, 2022, 14, 26.	3.0	49
15	Comparing tau status determined via plasma pTau181, pTau231 and [18F]MK6240 tau-PET. EBioMedicine, 2022, 76, 103837.	2.7	34
16	Plasma and CSF NfL are differentially associated with biomarker evidence of neurodegeneration in a community-based sample of 70-year-olds. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2022, 14, e12295.	1.2	11
17	CSF biomarkers and plasma p τ ₁₈₁ as predictors of longitudinal tau accumulation: Implications for clinical trial design. Alzheimer's and Dementia, 2022, 18, 2614-2626.	0.4	22
18	Plasma biomarkers for Alzheimer's Disease in relation to neuropathology and cognitive change. Acta Neuropathologica, 2022, 143, 487-503.	3.9	89

#	ARTICLE	IF	CITATIONS
19	Brain Injury Biomarkers for Predicting Outcome After Cardiac Arrest. <i>Critical Care</i> , 2022, 26, 81.	2.5	15
20	Post-acute blood biomarkers and disease progression in traumatic brain injury. <i>Brain</i> , 2022, 145, 2064-2076.	3.7	37
21	Differences Between Plasma and Cerebrospinal Fluid p-tau181 and p-tau231 in Early Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2022, 87, 991-997.	1.2	10
22	Effect of Race on Prediction of Brain Amyloidosis by Plasma A β 42/A β 40, Phosphorylated Tau, and Neurofilament Light. <i>Neurology</i> , 2022, 99, .	1.5	63
23	Biomarker modeling of Alzheimer's disease using PET-based Braak staging. <i>Nature Aging</i> , 2022, 2, 526-535.	5.3	73
24	Alzheimer's Disease Plasma Biomarkers Distinguish Clinical Diagnostic Groups in Memory Clinic Patients. <i>Dementia and Geriatric Cognitive Disorders</i> , 2022, 51, 182-192.	0.7	16
25	Ante-mortem plasma phosphorylated tau (181) predicts Alzheimer's disease neuropathology and regional tau at autopsy. <i>Brain</i> , 2022, 145, 3546-3557.	3.7	15
26	Diagnostic value of serum versus plasma phospho-tau for Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2022, 14, 65.	3.0	25
27	Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility. <i>Nature Reviews Neurology</i> , 2022, 18, 400-418.	4.9	99
28	Population-based blood screening for pre-clinical Alzheimer's disease: a British birth cohort at age 70. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, A91.2-A91.	0.9	0
29	Quantification of SNAP-25 with mass spectrometry and Simoa: a method comparison in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2022, 14, .	3.0	11
30	Plasma phospho-tau181 in presymptomatic and symptomatic familial Alzheimer's disease: a longitudinal cohort study. <i>Molecular Psychiatry</i> , 2021, 26, 5967-5976.	4.1	76
31	Determining Amyloid- β Positivity Using ¹⁸ F-AZD4694 PET Imaging. <i>Journal of Nuclear Medicine</i> , 2021, 62, 247-252.	2.8	65
32	Head-to-head comparison of clinical performance of CSF phospho-tau T181 and T217 biomarkers for Alzheimer's disease diagnosis. <i>Alzheimer's and Dementia</i> , 2021, 17, 755-767.	0.4	81
33	Time course of phosphorylated-tau181 in blood across the Alzheimer's disease spectrum. <i>Brain</i> , 2021, 144, 325-339.	3.7	124
34	Plasma neurofilament light chain as a potential biomarker in Charcot-Marie-Tooth disease. <i>European Journal of Neurology</i> , 2021, 28, 974-981.	1.7	30
35	Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer's Disease Neuroimaging Initiative. <i>Molecular Psychiatry</i> , 2021, 26, 429-442.	4.1	186
36	Neurofilament light as an outcome predictor after cardiac arrest: a post hoc analysis of the COMACARE trial. <i>Intensive Care Medicine</i> , 2021, 47, 39-48.	3.9	90

#	ARTICLE	IF	CITATIONS
37	Effects of pre-analytical procedures on blood biomarkers for Alzheimer's pathophysiology, glial activation, and neurodegeneration. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12168.	1.2	52
38	Blood neurofilament light in remote settings: Alternative protocols to support sample collection in challenging pre-analytical conditions. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12145.	1.2	17
39	Biomarkers for central nervous system injury in cerebrospinal fluid are elevated in COVID-19 and associated with neurological symptoms and disease severity. <i>European Journal of Neurology</i> , 2021, 28, 3324-3331.	1.7	109
40	Head-to-head comparison of amplified plasmonic exosome A β 242 platform and single-molecule array immunoassay in a memory clinic cohort. <i>European Journal of Neurology</i> , 2021, 28, 1479-1489.	1.7	11
41	Association between polygenic risk score of Alzheimer's disease and plasma phosphorylated tau in individuals from the Alzheimer's Disease Neuroimaging Initiative. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 17.	3.0	35
42	Plasma p-tau231: a new biomarker for incipient Alzheimer's disease pathology. <i>Acta Neuropathologica</i> , 2021, 141, 709-724.	3.9	285
43	Plasma p-tau181 to A β 242 ratio is associated with brain amyloid burden and hippocampal atrophy in an Asian cohort of Alzheimer's disease patients with concomitant cerebrovascular disease. <i>Alzheimer's and Dementia</i> , 2021, 17, 1649-1662.	0.4	37
44	Proteomic blood profiling in mild, severe and critical COVID-19 patients. <i>Scientific Reports</i> , 2021, 11, 6357.	1.6	72
45	Replication study of plasma proteins relating to Alzheimer's pathology. <i>Alzheimer's and Dementia</i> , 2021, 17, 1452-1464.	0.4	13
46	The strategic biomarker roadmap for the validation of Alzheimer's diagnostic biomarkers: methodological update. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2070-2085.	3.3	22
47	Plasma pTau181 predicts cortical brain atrophy in aging and Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 69.	3.0	34
48	Plasma levels of phosphorylated tau 181 are associated with cerebral metabolic dysfunction in cognitively impaired and amyloid-positive individuals. <i>Brain Communications</i> , 2021, 3, fcab073.	1.5	15
49	Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease. <i>JAMA Neurology</i> , 2021, 78, 396.	4.5	146
50	Saliva Neurofilament Light Chain Is Not a Diagnostic Biomarker for Neurodegeneration in a Mixed Memory Clinic Population. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 659898.	1.7	9
51	Complex Autoantibody Responses Occur following Moderate to Severe Traumatic Brain Injury. <i>Journal of Immunology</i> , 2021, 207, 90-100.	0.4	24
52	Use of plasma biomarkers for AT(N) classification of neurodegenerative dementias. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 1206-1214.	0.9	30
53	Plasma NfL, clinical subtypes and motor progression in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2021, 87, 41-47.	1.1	26
54	Spitting image: can saliva biomarkers reflect Alzheimer's disease?. <i>EBioMedicine</i> , 2021, 68, 103437.	2.7	9

#	ARTICLE	IF	CITATIONS
55	A multicentre validation study of the diagnostic value of plasma neurofilament light. <i>Nature Communications</i> , 2021, 12, 3400.	5.8	219
56	Association of plasma P-tau181 with memory decline in non-demented adults. <i>Brain Communications</i> , 2021, 3, fcab136.	1.5	33
57	The reliability and validity of DSM 5 diagnostic criteria for neurocognitive disorder and relationship with plasma neurofilament light in a down syndrome population. <i>Scientific Reports</i> , 2021, 11, 13438.	1.6	6
58	Associations of Fully Automated CSF and Novel Plasma Biomarkers With Alzheimer Disease Neuropathology at Autopsy. <i>Neurology</i> , 2021, 97, .	1.5	50
59	Phosphorylated tau181 in plasma as a potential biomarker for Alzheimer's disease in adults with Down syndrome. <i>Nature Communications</i> , 2021, 12, 4304.	5.8	33
60	Plasma GFAP is an early marker of amyloid- β^2 but not tau pathology in Alzheimer's disease. <i>Brain</i> , 2021, 144, 3505-3516.	3.7	198
61	Critical illness polyneuropathy, myopathy and neuronal biomarkers in COVID-19 patients: A prospective study. <i>Clinical Neurophysiology</i> , 2021, 132, 1733-1740.	0.7	94
62	Neurochemical signs of astrocytic and neuronal injury in acute COVID-19 normalizes during long-term follow-up. <i>EBioMedicine</i> , 2021, 70, 103512.	2.7	106
63	Microglial activation and tau propagate jointly across Braak stages. <i>Nature Medicine</i> , 2021, 27, 1592-1599.	15.2	235
64	Synaptic Molecular and Neurophysiological Markers Are Independent Predictors of Progression in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2021, 83, 355-366.	1.2	1
65	Plasma Neurofilament Light Chain Predicts Cognitive Progression in Prodromal and Clinical Dementia with Lewy Bodies. <i>Journal of Alzheimer's Disease</i> , 2021, 82, 913-919.	1.2	27
66	Ultra-Early Differential Diagnosis of Acute Cerebral Ischemia and Hemorrhagic Stroke by Measuring the Prehospital Release Rate of GFAP. <i>Clinical Chemistry</i> , 2021, 67, 1361-1372.	1.5	21
67	Comparison of Plasma Phosphorylated Tau Species With Amyloid and Tau Positron Emission Tomography, Neurodegeneration, Vascular Pathology, and Cognitive Outcomes. <i>JAMA Neurology</i> , 2021, 78, 1108.	4.5	114
68	Blood-based high sensitivity measurements of beta-amyloid and phosphorylated tau as biomarkers of Alzheimer's disease: a focused review on recent advances. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 1231-1241.	0.9	51
69	A genome-wide association study of plasma phosphorylated tau181. <i>Neurobiology of Aging</i> , 2021, 106, 304.e1-304.e3.	1.5	5
70	The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, 1145-1156.	0.4	174
71	Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Encephalitis Is a Cytokine Release Syndrome: Evidences From Cerebrospinal Fluid Analyses. <i>Clinical Infectious Diseases</i> , 2021, 73, e3019-e3026.	2.9	131
72	Serum and cerebrospinal fluid biomarker profiles in acute SARS-CoV-2-associated neurological syndromes. <i>Brain Communications</i> , 2021, 3, fcab099.	1.5	43

#	ARTICLE	IF	CITATIONS
73	OUP accepted manuscript. Brain, 2021, 144, 434-449.	3.7	54
74	Plasma sTREM2: a potential marker of cerebrovascular injury in neurodegenerative disorders. Brain, 2021, 144, 3283-3285.	3.7	5
75	Changes in Blood Biomarkers of Brain Injury and Degeneration Following Long-Duration Spaceflight. JAMA Neurology, 2021, 78, 1525.	4.5	19
76	P-tau235: a novel biomarker for staging preclinical Alzheimer's disease. EMBO Molecular Medicine, 2021, 13, e15098.	3.3	30
77	Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum. JAMA Neurology, 2021, 78, 1471.	4.5	204
78	Prodromal frontotemporal dementia: clinical features and predictors of progression. Alzheimer's Research and Therapy, 2021, 13, 188.	3.0	8
79	Detecting amyloid positivity in early Alzheimer disease using plasma biomarkers. Alzheimer's and Dementia, 2021, 17, .	0.4	6
80	Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau231. Alzheimer's Research and Therapy, 2021, 13, 198.	3.0	87
81	Tau368 in cerebrospinal fluid is associated with severity of tau pathology load in the Alzheimer's disease continuum. Alzheimer's and Dementia, 2021, 17, .	0.4	1
82	Neurochemical signs of astrocytic and neuronal injury in acute COVID-19 normalizes during long-term follow-up. Alzheimer's and Dementia, 2021, 17, .	0.4	2
83	CSF apolipoprotein B levels predict future visuospatial cognitive decline and synaptic pathology in cognitively unimpaired healthy elderly with a parental history of Alzheimer's disease. Alzheimer's and Dementia, 2021, 17, .	0.4	1
84	Plasma glial fibrillary acidic protein is an early and specific marker of amyloid β pathology in Alzheimer's disease. Alzheimer's and Dementia, 2021, 17, .	0.4	1
85	Plasma p-tau231 in the Alzheimer's disease continuum: A multi-cohort evaluation of diagnostic performance, detection of A β pathology and preclinical application. Alzheimer's and Dementia, 2021, 17, .	0.4	0
86	Distinctive effect of biological sex in AD-related CSF and plasma biomarkers. Alzheimer's and Dementia, 2021, 17, .	0.4	2
87	Brain atrophy and white matter hyperintensities are independently associated with plasma neurofilament light chain in an Asian cohort of patients with mixed pathology. Alzheimer's and Dementia, 2021, 17, .	0.4	0
88	Plasma p-tau181 and p-tau231 offer complementary information to identify Alzheimer's disease pathophysiology. Alzheimer's and Dementia, 2021, 17, .	0.4	1
89	CSF and PET biomarkers for noradrenergic dysfunction in neurodegenerative disease: A systematic review and meta-analysis. Alzheimer's and Dementia, 2021, 17, .	0.4	0
90	Plasma biomarkers distinguish clinical diagnostic groups in memory clinic patients. Alzheimer's and Dementia, 2021, 17, .	0.4	0

#	ARTICLE	IF	CITATIONS
91	Mass spectrometric measurement of six site-specific tau phosphorylations in CSF and blood of Alzheimer's disease patients. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
92	Plasma p-tau ₁₈₁ and NfL are central nodes in a network of diagnostic, biomarker, and demographic data. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
93	Microglial activation and tau propagate jointly across Braak stages. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	4
94	Associations of fully automated Elecsys CSF and novel plasma biomarkers with Alzheimer's disease neuropathology. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
95	Association of cerebrospinal fluid and plasma biomarkers with longitudinal tau accumulation. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
96	Plasma and cerebrospinal fluid neurofilament light protein concentrations are differentially associated with biomarker evidence of neurodegeneration in a community-based population of 70-year-olds. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
97	Association of deep-learning-derived brain computed tomography measures with cognition and blood-based biomarkers of neurodegenerative diseases. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
98	Plasma biomarkers for the AT(N) classification and for the detection of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
99	Propagation of Tau Pathology: Integrating Insights From Postmortem and In Vivo Studies. <i>Biological Psychiatry</i> , 2020, 87, 808-818.	0.7	50
100	An update on fluid biomarkers for neurodegenerative diseases: recent success and challenges ahead. <i>Current Opinion in Neurobiology</i> , 2020, 61, 29-39.	2.0	67
101	Comparing Glial Fibrillary Acidic Protein (GFAP) in Serum and Plasma Following Mild Traumatic Brain Injury in Older Adults. <i>Frontiers in Neurology</i> , 2020, 11, 1054.	1.1	45
102	Stage-specific links between plasma neurofilament light and imaging biomarkers of Alzheimer's disease. <i>Brain</i> , 2020, 143, 3793-3804.	3.7	60
103	Plasma p-tau181 accurately predicts Alzheimer's disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline. <i>Acta Neuropathologica</i> , 2020, 140, 267-278.	3.9	209
104	Serum Glial Fibrillary Acidic Protein (GFAP) Is a Marker of Disease Severity in Frontotemporal Lobar Degeneration. <i>Journal of Alzheimer's Disease</i> , 2020, 77, 1129-1141.	1.2	55
105	Dickkopf-1 Overexpression in vitro Nominates Candidate Blood Biomarkers Relating to Alzheimer's Disease Pathology. <i>Journal of Alzheimer's Disease</i> , 2020, 77, 1353-1368.	1.2	7
106	Fluid Biomarkers for Synaptic Dysfunction and Loss. <i>Biomarker Insights</i> , 2020, 15, 117727192095031.	1.0	74
107	Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer's <i>continuum</i> when only subtle changes in A β pathology are detected. <i>EMBO Molecular Medicine</i> , 2020, 12, e12921.	3.3	202
108	Full-length and C-terminal neurogranin in Alzheimer's disease cerebrospinal fluid analyzed by novel ultrasensitive immunoassays. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 168.	3.0	7

#	ARTICLE	IF	CITATIONS
109	Identification of plasma proteome signatures associated with ATN framework using SOMAscan. <i>Alzheimer's and Dementia</i> , 2020, 16, e036954.	0.4	1
110	Alzheimer's disease biomarker roadmap 2020: [18 F]flortaucipir. <i>Alzheimer's and Dementia</i> , 2020, 16, e039550.	0.4	0
111	Alzheimer's disease biomarker roadmap 2020: Second-generation tau PET tracers. <i>Alzheimer's and Dementia</i> , 2020, 16, e039556.	0.4	1
112	Alzheimer's disease biomarker roadmap 2020: Fluid biomarkers. <i>Alzheimer's and Dementia</i> , 2020, 16, e039557.	0.4	2
113	Serum NFL as a predictor of disease progression in dementia with Lewy bodies. <i>Alzheimer's and Dementia</i> , 2020, 16, e041594.	0.4	0
114	Ultrasensitive blood biomarkers to predict cognitive decline and diagnose Alzheimer's disease in the absence of AT(N) classification as the reference standard. <i>Alzheimer's and Dementia</i> , 2020, 16, e041808.	0.4	1
115	Amyloid β , tau, synaptic dysfunction, neurodegeneration, glial and vascular biomarkers in the preclinical stage of the Alzheimer's continuum. <i>Alzheimer's and Dementia</i> , 2020, 16, e044444.	0.4	0
116	The effect of physical activity on CSF biomarkers of Alzheimer's disease differs between men and women. <i>Alzheimer's and Dementia</i> , 2020, 16, e044722.	0.4	0
117	Plasma p-tau181 accurately predicts Alzheimer's disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline. <i>Alzheimer's and Dementia</i> , 2020, 16, e047539.	0.4	2
118	Alzheimer's disease biomarker roadmap 2020: Time for tau. <i>Alzheimer's and Dementia</i> , 2020, 16, e039549.	0.4	3
119	Urinary metabolic phenotyping for Alzheimer's disease. <i>Scientific Reports</i> , 2020, 10, 21745.	1.6	30
120	Steroid-Responsive Encephalitis in Coronavirus Disease 2019. <i>Annals of Neurology</i> , 2020, 88, 423-427.	2.8	230
121	Validation of Plasma Proteomic Biomarkers Relating to Brain Amyloid Burden in the EMIF-Alzheimer's Disease Multimodal Biomarker Discovery Cohort. <i>Journal of Alzheimer's Disease</i> , 2020, 74, 213-225.	1.2	13
122	Relevance of biomarkers across different neurodegenerative diseases. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 56.	3.0	42
123	Neurochemical evidence of astrocytic and neuronal injury commonly found in COVID-19. <i>Neurology</i> , 2020, 95, e1754-e1759.	1.5	304
124	Plasma transferrin and hemopexin are associated with altered A β uptake and cognitive decline in Alzheimer's disease pathology. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 72.	3.0	19
125	Diagnostic and prognostic value of serum NfL and p-Tau ₁₈₁ in frontotemporal lobar degeneration. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 960-967.	0.9	93
126	Serum Hepcidin Levels in Cognitively Normal Older Adults with High Neocortical Amyloid- β Load. <i>Journal of Alzheimer's Disease</i> , 2020, 76, 291-301.	1.2	3

#	ARTICLE	IF	CITATIONS
127	Perspectives in fluid biomarkers in neurodegeneration from the 2019 biomarkers in neurodegenerative diseases course—a joint PhD student course at University College London and University of Gothenburg. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 20.	3.0	32
128	An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders. <i>Nature Reviews Neurology</i> , 2020, 16, 265-284.	4.9	121
129	Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. <i>Lancet Neurology</i> , The, 2020, 19, 422-433.	4.9	668
130	Steroid-Responsive Encephalitis in Coronavirus Disease 2019. , 2020, 88, 423.		1
131	Plasma neurofilament light chain and amyloid- β^2 are associated with the kynurenine pathway metabolites in preclinical Alzheimer's disease. <i>Journal of Neuroinflammation</i> , 2019, 16, 186.	3.1	41
132	Comparative analysis of obesity-related cardiometabolic and renal biomarkers in human plasma and serum. <i>Scientific Reports</i> , 2019, 9, 15385.	1.6	19
133	Increased plasma neurofilament light chain concentration correlates with severity of post-mortem neurofibrillary tangle pathology and neurodegeneration. <i>Acta Neuropathologica Communications</i> , 2019, 7, 5.	2.4	125
134	Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay. <i>Alzheimer's and Dementia</i> , 2019, 15, 1478-1488.	0.4	46
135	Plasma neurofilament light associates with Alzheimer's disease metabolic decline in amyloid- β positive individuals. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 679-689.	1.2	48
136	Primary fatty amides in plasma associated with brain amyloid burden, hippocampal volume, and memory in the European Medical Information Framework for Alzheimer's Disease biomarker discovery cohort. <i>Alzheimer's and Dementia</i> , 2019, 15, 817-827.	0.4	62
137	Plasma biomarkers for amyloid, tau, and cytokines in Down syndrome and sporadic Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 26.	3.0	56
138	Synaptic vesicle protein 2A as a potential biomarker in synaptopathies. <i>Molecular and Cellular Neurosciences</i> , 2019, 97, 34-42.	1.0	55
139	A plasma protein classifier for predicting amyloid burden for preclinical Alzheimer's disease. <i>Science Advances</i> , 2019, 5, eaau7220.	4.7	59
140	F4-05-01: ASSOCIATIONS BETWEEN PLASMA NFL AND BRAIN PET IN ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2019, 15, P1224.	0.4	0
141	O2-05-01: CEREBROSPINAL FLUID SYNAPTIC VESICLE GLYCOPROTEIN 2A IN ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2019, 15, P545.	0.4	2
142	IC-PA-070: ASSOCIATIONS BETWEEN PLASMA NFL AND BRAIN PET IN THE ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2019, 15, P64.	0.4	1
143	IC-PA-071: ASSOCIATIONS BETWEEN PLASMA NFL AND BRAIN ATROPHY IN ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2019, 15, P65.	0.4	0
144	IC-PA-072: LONGITUDINAL ASSOCIATIONS BETWEEN PLASMA NFL AND VOXEL-BASED MORPHOMETRY IN ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2019, 15, P66.	0.4	0

#	ARTICLE	IF	CITATIONS
145	Plasma levels of soluble TREM2 and neurofilament light chain in TREM2 rare variant carriers. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 94.	3.0	20
146	Salivary Biomarkers for Alzheimer's Disease and Related Disorders. <i>Neurology and Therapy</i> , 2019, 8, 83-94.	1.4	54
147	Biomarkers for tau pathology. <i>Molecular and Cellular Neurosciences</i> , 2019, 97, 18-33.	1.0	163
148	P3-243: THE ASSOCIATION OF LONGITUDINAL PLASMA NFL WITH POSTMORTEM NEUROPATHOLOGY. <i>Alzheimer's and Dementia</i> , 2018, 14, P1165.	0.4	0
149	P3-233: PLASMA PRIMARY FATTY AMIDES ASSOCIATE TO CSF AMYLOID LEVELS AND ALZHEIMER'S DISEASE PROGRESSION IN THE EMIFAD BIOMARKER DISCOVERY COHORT. <i>Alzheimer's and Dementia</i> , 2018, 14, P1161.	0.4	0
150	Plasma Protein Biomarkers for the Prediction of CSF Amyloid and Tau and [18F]-Flutemetamol PET Scan Result. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 409.	1.7	28
151	No association of salivary total tau concentration with Alzheimer's disease. <i>Neurobiology of Aging</i> , 2018, 70, 125-127.	1.5	51
152	Update on biomarkers for amyloid pathology in Alzheimer's disease. <i>Biomarkers in Medicine</i> , 2018, 12, 799-812.	0.6	59
153	Detection of Alzheimer's Disease. <i>Yale Journal of Biology and Medicine</i> , 2018, 91, 291-300.	0.2	21
154	[P3-209]: EX-VIVO VALIDATION OF PLASMA PROTEIN FIBRINOGEN GAMMA. <i>Alzheimer's and Dementia</i> , 2017, 13, P1016.	0.4	0
155	[P3-243]: A MASS SPECTROMETRY-BASED DISCOVERY AND REPLICATION OF A MULTI-ANALYTE CLASSIFIER FOR NEOCORTICAL AMYLOID PATHOLOGY. <i>Alzheimer's and Dementia</i> , 2017, 13, P1033.	0.4	0
156	Blood-Based Biomarker Candidates of Cerebral Amyloid Using PiB PET in Non-Demented Elderly. <i>Journal of Alzheimer's Disease</i> , 2016, 52, 561-572.	1.2	41
157	P3-154: Plasma Biomarkers of Neocortical Amyloid Burden: An in-Depth Plasma Profile Using LC-MS. <i>Alzheimer's and Dementia</i> , 2016, 12, P878.	0.4	0
158	O4-10-02: Blood-Based Rest Protein Levels Vary by Clinical Group and are Associated with Alzheimer's Disease Biomarkers. <i>Alzheimer's and Dementia</i> , 2016, 12, P357.	0.4	0
159	S4-01-01: Cross-Sectional Studies of Plasma Proteomic Biomarkers Relating to Pet Amyloid and CSF Amyloid and Tau. , 2016, 12, P321-P321.		0
160	Blood protein predictors of brain amyloid for enrichment in clinical trials?. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2015, 1, 48-60.	1.2	50
161	Plasma proteins predict conversion to dementia from prodromal disease. <i>Alzheimer's and Dementia</i> , 2014, 10, 799.	0.4	180
162	P3-108: DISCOVERY AND VALIDATION OF PLASMA BIOMARKERS RELATING TO CSF MEASURES OF ALZHEIMER'S DISEASE PATHOLOGY. , 2014, 10, P668-P668.		0

#	ARTICLE	IF	CITATIONS
163	P3-113: NOVEL CANDIDATE BLOOD PROTEOME MARKERS OF ALZHEIMER'S DISEASE BRAIN AMYLOID BURDEN: A MULTIPLEX TMT-LC/MS-MS DISCOVERY APPROACH. , 2014, 10, P669-P670.		0